168 related articles for article (PubMed ID: 24485040)
1. High ALDH1A1 expression correlates with poor survival in papillary thyroid carcinoma.
Xing Y; Luo DY; Long MY; Zeng SL; Li HH
World J Surg Oncol; 2014 Feb; 12():29. PubMed ID: 24485040
[TBL] [Abstract][Full Text] [Related]
2. Thyroid cancer in Egypt: histopathological criteria, correlation with survival and oestrogen receptor protein expression.
Ahmed RA; Aboelnaga EM
Pathol Oncol Res; 2015 Jul; 21(3):793-802. PubMed ID: 25576212
[TBL] [Abstract][Full Text] [Related]
3. [High aldehyde dehydrogenase 1A1 (ALDH1A1) expression correlated with risk of lymph node metastasis in papillary thyroid carcinoma].
Yue C; Zhao X; Tian C; Jin Y; Liu H
Zhonghua Bing Li Xue Za Zhi; 2015 Jul; 44(7):490-4. PubMed ID: 26705040
[TBL] [Abstract][Full Text] [Related]
4. Associations of carboxypeptidase 4 with ALDH1A1 expression and their prognostic value in esophageal squamous cell carcinoma.
Sun L; Cao J; Guo C; Burnett J; Yang Z; Ran Y; Sun D
Dis Esophagus; 2017 Jun; 30(6):1-5. PubMed ID: 28475748
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of nuclear receptor coactivator amplified in breast cancer-1 in papillary thyroid carcinoma correlates with lymph node metastasis.
Liu MY; Guo HP; Hong CQ; Peng HW; Yang XH; Zhang H
Clin Transl Oncol; 2013 Nov; 15(11):947-52. PubMed ID: 23606350
[TBL] [Abstract][Full Text] [Related]
6. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival.
Akslen LA; Varhaug JE
Cancer; 1995 Nov; 76(9):1643-54. PubMed ID: 8635070
[TBL] [Abstract][Full Text] [Related]
7. Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.
Chereau N; Dauzier E; Godiris-Petit G; Noullet S; Brocheriou I; Leenhardt L; Buffet C; Menegaux F
Langenbecks Arch Surg; 2018 May; 403(3):325-332. PubMed ID: 29445865
[TBL] [Abstract][Full Text] [Related]
8. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
Jia M; Guo Y; Lu X
Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
[TBL] [Abstract][Full Text] [Related]
9. Expression of ki67 in papillary thyroid microcarcinoma and its clinical significance.
Zhou Y; Jiang HG; Lu N; Lu BH; Chen ZH
Asian Pac J Cancer Prev; 2015; 16(4):1605-8. PubMed ID: 25743839
[TBL] [Abstract][Full Text] [Related]
10. Osteopontin levels in patients with papillary thyroid cancer according to the presence of Hashimoto's thyroiditis.
Park SH; Park CS; Kim YI; Nam-Goong IS; Kim YS; Lee JC; Choi JI; Park JW; Kim ES
Asian Pac J Cancer Prev; 2015; 16(6):2447-51. PubMed ID: 25824779
[TBL] [Abstract][Full Text] [Related]
11. High Expression of Angiopoietin-1 is Associated with Lymph Node Metastasis and Invasiveness of Papillary Thyroid Carcinoma.
Kang YE; Kim KS; Park SJ; Jung SN; Chang JW; Yi S; Jung MG; Kim JM; Koo BS
World J Surg; 2017 Dec; 41(12):3128-3138. PubMed ID: 28717903
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of ALDH1A1 protein is associated with poor prognosis in clear cell renal cell carcinoma.
Wang K; Chen X; Zhan Y; Jiang W; Liu X; Wang X; Wu B
Med Oncol; 2013; 30(2):574. PubMed ID: 23585015
[TBL] [Abstract][Full Text] [Related]
13. ALDH1A1 overexpression is associated with the progression and prognosis in gastric cancer.
Li XS; Xu Q; Fu XY; Luo WS
BMC Cancer; 2014 Sep; 14():705. PubMed ID: 25253129
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer.
Alamgeer M; Ganju V; Szczepny A; Russell PA; Prodanovic Z; Kumar B; Wainer Z; Brown T; Schneider-Kolsky M; Conron M; Wright G; Watkins DN
Thorax; 2013 Dec; 68(12):1095-104. PubMed ID: 23878161
[TBL] [Abstract][Full Text] [Related]
15. Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy.
Khoury T; Ademuyiwa FO; Chandrasekhar R; Jabbour M; Deleo A; Ferrone S; Wang Y; Wang X
Mod Pathol; 2012 Mar; 25(3):388-97. PubMed ID: 22080062
[TBL] [Abstract][Full Text] [Related]
16. Improvement of lymph node recurrence rate, but not distant recurrence and carcinoma death rates, in patients with papillary thyroid carcinoma after disease-free survival for 5 years.
Ito Y; Kudo T; Kihara M; Takamura Y; Kobayashi K; Miya A; Miyauchi A
Endocr J; 2012; 59(10):895-901. PubMed ID: 22785260
[TBL] [Abstract][Full Text] [Related]
17. Impact of invasive extranodal extension on the prognosis of patients with papillary thyroid carcinoma.
Moritani S
Thyroid; 2014 Dec; 24(12):1779-83. PubMed ID: 25157399
[TBL] [Abstract][Full Text] [Related]
18. Dynamin 2 Is Correlated with Recurrence and Poor Prognosis of Papillary Thyroid Cancer.
Ren N; Tian Z; Sun H; Lu X
Med Sci Monit; 2020 Aug; 26():e924590. PubMed ID: 32827429
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of serum DKK-1 predicts poor prognosis in patients with papillary thyroid cancer.
Zhao YP; Wang W; Wang XH; Xu Y; Wang Y; Dong ZF; Zhang JJ
Genet Mol Res; 2015 Dec; 14(4):18886-94. PubMed ID: 26782539
[TBL] [Abstract][Full Text] [Related]
20. Strong expression of HBME-1 associates with high-risk clinicopathological factors of papillary thyroid carcinoma.
Dencic TM; Savin SB; Selemetjev SA; Paskas SD; Zivaljevic VR; Bozic VD; Cvejic DS
Pathol Oncol Res; 2015 Jul; 21(3):735-42. PubMed ID: 25577274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
